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Abstract  
Epstein-Barr virus (EBV) associated Burkitt’s lymphoma is characterised by the deregulation 
of c-Myc expression and a restricted viral gene expression pattern in which the EBV nuclear 
antigen-1 (EBNA1) is the only viral protein to be consistently expressed. EBNA1 is required 
for viral genome propagation and segregation during latency. However, it has been much 
debated whether the protein plays a role in viral-associated tumourigenesis. We show that the 
lymphomas which arise in EµEBNA1 transgenic mice are unequivocally linked to EBNA1 
expression and that both C-Myc and Mdm2 deregulation are central to this process. Tumour 
cell survival is supported by IL-2 and there is a skew towards CD8 positive T-cells in the 
tumour environment, while the immune check-point protein PD-L1 is upregulated in the 
tumours. Additionally, several isoforms of Mdm2 are upregulated in the EµEBNA1 tumours, 
with increased phosphorylation at ser166, an expression pattern not seen in Eµc-Myc 
transgenic tumours. Concomitantly, E2F1, Xiap, Mta1, C-Fos and Stat1 are upregulated in the 
tumours. Using four independent inhibitors of Mdm2 we demonstrate that the EµEBNA1 
tumour cells are dependant upon Mdm2 for survival (as they are upon c-Myc) and that Mdm2 
inhibition is not accompanied by upregulation of p53, instead cell death is linked to loss of 
E2F1 expression, providing new insight into the underlying tumourigenic mechanism. This 
opens a new path to combat EBV-associated disease.  
 
Introduction  
The human gammaherpesvirus Epstein-Barr virus (EBV) is causally associated with several 
malignancies of epithelial and B-cell origin, including nasopharyngeal carcinoma (NPC) and 
Burkitt’s lymphoma (BL). The Epstein-Barr virus nuclear antigen 1 (EBNA1) is a 
multifunctional DNA binding protein which is essential for the lifelong persistence of the 
virus in the host. It plays a vital role in viral genome replication and is required for efficient 
mitotic segregation during latent infection 1. The protein also acts as a transcriptional 
regulator of both viral and host promoters 2. EBNA1 achieves its functions by binding to viral 
and host DNA, host proteins and RNA 3, 4. In addition, it was recently discovered that the 
gly/ala repeat (GAr) region of EBNA1 that mediates translation suppression, leads to a stress 
response which promotes E2F1 translation 5.  
While clearly pleiotropic, the role of EBNA1 in EBV associated malignancies has 
remained enigmatic. We previously reported that B-cell directed expression of EBNA1 
predisposed transgenic mice to B-cell lymphoma, suggesting a direct role for the protein in 
lymphoid malignancies, particularly BL 6. In two transgenic lines expressing the transgene, 
we showed a curious inverse relationship between the level of EBNA1 protein and the 
incidence of lymphoma.  
There is now considerable evidence to support the hypothesis that EBNA1 has 
oncogenic activity. Inhibition of EBNA1 decreases the survival of EBV-positive BL cells and 
it was shown that EBNA1 could inhibit p53-mediated apoptosis 7. Further, EBNA1 interacts 
with the ubiquitin specific protease USP7, an enzyme which removes ubiquitin groups from 
its target proteins, which include both p53 and Mdm2 8. EBNA1 has been shown to induce 
several transcription factors that regulate pathways important in tumourigeneisis, including 
STAT1 and AP1 complexes 9-11. This action may be mediated through EBNA1 as a DNA 
binding transcription factor; indeed EBNA1 binds to multiple DNA sequence sites in the 
cellular genome, including the promoters of genes which are transcriptionally upregulated by 
EBNA1, such as MEF2B, EBF1 and IL6R 12. Recently it has been found that EBNA1 can 
also influence cellular gene expression, including that of E2F1 and thence c-Myc, through a 
novel mechanism involving the GAr sequence of EBNA1 and the suppression of translation 
in cis. Importantly, this property is critically dependant upon the 5’ sequences (hypothesized 
to be important in the mRNA structure) and can be abrogated by altering these sequences 5. 
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In view of the mounting evidence indicating an oncogenic activity of EBNA1 and the 
importance of this protein, both in the viral life cycle and as a therapeutic target, we sought to 
clarify the role of EBNA1 in lymphoma development in our transgenic mouse model of EBV-
associated BL. Our data overwhelmingly point to EBNA1 as the causal oncogene in this 
system. We previously observed that chromosome 10, 15 and 17 amplifications were 
common in the EBNA1 transgenic mouse lymphomas and that the amplifications of 
chromosome 15 were driven by the selection for c-Myc induction 13. We hypothesized that 
Mdm2 might be a candidate underlying driving force for the chromosome 10 amplifications. 
We now show that specific isoforms of Mdm2 are consistently overexpressed in these 
EBNA1-driven tumours and this is distinct from transgenic c-Myc driven tumours. Moreover, 
inhibition of Mdm2 in the EµEBNA1 tumour cells leads to a dramatic down regulation of 
EBNA1 and particularly E2F1 expression, accompanied by the death of the cells. 
 
Results  
Low level expression of EBNA1 drives the tumour phenotype in EµEBNA1 line 26 
Our transgenic mice were originally generated to model the viral contribution to BL, by 
expressing EBNA1 in B-cell cells. Two lines of EµEBNA1 transgenic mice were generated 
which expressed EBNA1 in the B-cell compartment (designated 26 and 59) 14. Surprisingly, 
mice of line 26, which showed lower EBNA1 steady-state protein levels in pre-neoplastic 
lymphoid tissues compared to line 59 (despite equivalent transcript levels), displayed greater 
penetrance of the lymphoma phenotype 6, 14, 15.  
Both transgenic lines (EµEBNA1.26 and 59) have been backcrossed into the C57Bl6/J 
strain for well over 70 generations and the phenotype remains unchanged, ruling out the 
possibility that mutations elsewhere in the genome could be responsible for the tumour 
phenotype. Therefore the lymphoma phenotype maps unequivocally to the transgene locus in 
each case. Crossing mice of the line 26 to other commonly used laboratory mouse strains, 
BalbC and FVB, revealed that the background strain can influence disease latency, but not the 
characteristics of the tumour or the penetrance, which remained at 100% for this line (Fig. 
1A). Crossing the two lines together, to generate 2659 bitransgenic mice, showed no 
difference in lymphoma incidence compared to that of line 26 alone (Fig. 1B), showing that 
the higher expression levels of line 59 are not inhibitory to tumour development. 
In order to explore if a cellular gene was disrupted or deregulated at the site of 
transgene insertion, the integration sites were identified. Fluorescence in situ hybridization 
(FISH) of metaphase chromosomes derived from splenic cells from mice of each line, along 
with chromosomal painting, revealed that the transgene was integrated into chromosome 4 
band D in line 59 and chromosome 5 band B in line 26 (Fig. 2). Subsequent cloning and 
sequencing confirmed these integration sites (detailed in SI-1, figures S1, S2 and S3). The 
integration site for the dimeric transgene unit of line 59 maps to mouse chromosome 4 at 
130.88Mb. This site does not lie within any known gene, the closest mapping 36kb distal is 
lysosomal-associated protein (Laptm5 at 130.91Mb) which has no known oncogenic function 
(Fig 2C). The integration site of line 26 was mapped to chromosome 5 at 41.604Mb. There is 
a large gene-free region proximal to this site (3’ to the transgene unit), with heparan sulphate 
sulfotransferase-1 (Hs3st1) lying 2Mb away at 39.6Mb (Fig. 2C). Distal to the integration site 
(at 41.625Mb) is the 3’ end of the Rab28 gene, which encodes a protein of unknown function 
that is postulated to be involved in intracellular trafficking (with no known oncogenic 
activity). The Rab28 gene shows no rearrangements in line 26 and its expression is neither 
disrupted or deregulated by the transgene (SI-1 figure S4). 
Taking these data together, we have no evidence to suggest that disruption or 
deregulation of a cellular locus by the transgene, is causal in the lymphoma phenotype of 
either line 26 or 59, leading to the conclusion that EBNA1 is indeed the driving oncogene in 
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each case. Furthermore, the highly penetrant lymphoma phenotype of line 26, maps 
specifically to the line 26 transgene and is neither inhibited nor enhanced by higher levels of 
EBNA1, expressed from the line 59 transgene. Thus, it can be inferred that the pattern or 
nature of EBNA1 expression from the line 26 transgene is important in tumour development, 
consistent with the translation inhibition observed in line 26 6. 
 
IL-2 supports survival of the tumour cells and the tumour T-cell profile is distorted 
The EBNA1 expressing transgenic B-cells from both lines 26 and 59 prior to lymphoma 
development show prolonged survival in the presence of the T-cell cytokine IL-2 15, 16. 
Similarly, and consistent with our previous observation that the tumour B-cells are CD25 (IL-
2Rα) positive, addition of IL-2, and not IL-6 or IL-7, enhances the survival of the lymphoma 
cells in culture (Fig. 3A).  
IL-2 is primarily produced by T-cells and has profound and multiple effects upon both 
CD4 and CD8 populations 17. Analysis at explant, of the tumour resident T-cells showed that 
the proportion of CD8 verses CD4 T-cells is significantly skewed in the tumour bearing 
spleens (Fig. 3B-D), revealing an average 9.5 fold increase in the CD8:CD4 ratio. While there 
is a relative increase in the CD8 T-cell population within the tumour tissue, expression of the 
immune check-point protein PD-L1 is upregulated in the EµEBNA1.26 transgenic tumour 
tissue (not observed in the Eµc-Myc tumours), which would be predicted to inhibit T-cell 
effector functions (Fig. 3E). 
 
EBNA1 tumour cells cannot support inhibition of EBNA1  
Transfection of two B-cell lines developed from transgenic mouse lymphomas, with 
dominant-negative-EBNA1 (dnEBNA1) expression constructs, revealed that only the cell line 
which was derived from an EµEBNA1 expressing tumour was sensitive to EBNA1 inhibition 
(Fig. 4). The LMP1-positive mouse cell line (39.415) and the human BL cell line AK31, 
could support persistent expression of dnEBNA1 throughout selection and stable dnEBNA1-
expressing cell lines were established (Fig. 4). By contrast, with the LMP1+/EBNA1+ cell 
line (3959.48), dnEBNA1 expression was detected two days after transfection (Fig. 4C and 
D), was considerably reduced by 5 days and lost by two weeks of selection. All cultures and 
clones established following selection and stable retention of the G418-resistance encoding 
plasmid in this cell line, did not express dnEBNA1. This suggests that expression of 
dnEBNA1 is not compatible with the outgrowth of this LMP1/EBNA1 positive transgenic 
lymphoma cell line, which in turn indicates that EBNA1 provides a selectable growth 
advantage to the cells that can be inhibited by the dnEBNA1 proteins.  
 
Cellular genes deregulated by EBNA1 
EBNA1 is known to function as a transcriptional regulator and bind to cellular chromatin. In 
order to determine if EBNA1 deregulates the transcription of cellular genes in the line 26 
transgenic model, a global analysis of expressional changes was conducted using microarrays. 
Splenic B-cells from young mice were selected, at an age when the transgenic mice are 
phenotypically normal, with no evidence of lymphoma. This was chosen in order to 
specifically examine EBNA1 driven predisposition and to preclude the detection of 
expressional changes induced by mutations that occur through tumourigenesis. cDNA 
samples from 5 transgenics and 5 NSC were compared. Modest expression differences were 
observed: 89 genes showed a significant upregulation in the presence of EBNA1 and 46 
significant downregulation with a maximal difference of 4.45 fold (SI-2). Several of the 
identified genes have been previously published as targets of EBNA1-mediated deregulation, 
including Stat1, Id2 and AP1 family members (with c-Fos, FosB, JunB identified here) 9, 10.  
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To further explore any similarity between mouse and human cell responses to EBNA1, 
we compared this mouse gene set with a published set of genes identified as showing 
expressional changes at the RNA level (by RNAseq), following shRNA inhibition of EBNA1 
expression in human Mutu-EBV-positive lymphoblastoid cell line (LCL) 12. Of the 135 listed 
mouse genes (SI-2), a matched human homologue was identified for 114. Of these, 21 
showed significant changes at the gene or exon level in the human RNAseq data, with the 
same fold direction between EBNA1 present or absent (Fig. 5). Interestingly, one of these 
genes (Slc25a37, encoding a mitochondrial iron importer) also shows an EBNA1 binding site 
within 10kb from the transcriptional start site 12. As well as a notable preponderance of genes 
with a metabolic role in the common set, the marker of proliferation, Ki-67 is upregulated by 
EBNA1. 
Selected genes from the mouse list (SI-2) were examined for expression at the protein 
level in both human and mouse cell lines, as well as transgenic and control mouse tissue (Fig. 
6). C-Fos (one of two genes showing over 4 fold RNA upregulation in the presence of 
EBNA1) is expressed in both mouse B-cell lines examined and in the EBV positive human 
BL cell lines MutuI, MutuIII and Raji (at lower levels in MutuI), but is absent from the EBV 
negative cell line BL2. Interestingly, in the EBV converted BL2/B95.8 cell line c-Fos 
expression is induced compared to the parental BL2. C-Fos is upregulated in the EBNA1 
transgenic mouse tumour tissue while it is barely detectable in the normal lymph node tissues 
of NSC mice and pre-tumour, young EBNA1 transgenic mice. Similarly, Stat1 and its tyr701 
phosphorylated form (allowing dimerization and nuclear entry) are upregulated in the EBNA1 
transgenic mouse tumour tissues compared to normal tissue, and BL2/B95.8 compared to 
BL2 (the latter shows no expression). Stat1 is expressed and tyr701 phosphorylated in the 
Mutu cell lines. Proliferating cell nuclear antigen (PCNA), like Ki67 is a proliferation marker 
and is strongly expressed in all the cell lines examined and the transgenic EBNA1 tumours, 
with very low detection in the tissues of normal pathology. Contrary to the RNA data, FoxP1 
was readily detectable in all samples (cell lines and tissues), with possibly slightly higher 
levels in the EBNA1 transgenic tissues compared to NSC. 
 
EBNA1 driven tumours show upregulation of specific Mdm2 isoforms  
Prior to tumour development, the expression level of EBNA1 is very low in the line 26 B-
cells, but this substantially increases upon tumour development 14. Similarly the expression 
levels of both c-Myc and E2F1 are highly induced in the EBNA1 transgenic lymphomas (Fig. 
7). P53 is expressed at high levels in the EµEBNA1.26 tumour tissues, as well as tumours 
arising in Eµc-Myc mice and bitransgenic mice. The high levels of p53 in these tumour 
tissues suggest that it could be mutant, and indeed in some samples, p53 migrates at different 
sizes (Fig 7). The chromatin remodelling factor, metastatic tumour protein-1 (Mta1), a master 
co-regulator of oncogenes, can act to inhibit p53 ubiquitination and thereby contribute to its 
stabilisation 18. Interestingly, it is also induced in all of the EµEBNA1 tumours, but in only 1 
out of 3 of the Eµc-Myc tumours. Translation of the anti-apoptotic protein Xiap is promoted 
by Mdm2, through its C-terminal RING domain and this protein was also found to be 
upregulated in the EBNA1 tumours (Fig. 7). 
The Mdm2 gene produces numerous differentially spliced transcripts, encoding multiple 
isoforms of the protein, which have different functions 19-21. Using antibodies against different 
epitopes, including phosphorylated ser166, we found that several isoforms of Mdm2 are 
upregulated in the EBNA1 tumours. The major forms detected include: full length Mdm2 
(FL-Mdm2) phosphorylated on ser166, a 75kD ser166-phosphorylated isoform, an N-terminal 
50kD ser166-phosphorylated isoform and a tumour-specific highly abundant 70kD isoform 
(Fig. 7). A phospho-band detected at ~160kD may reflect a multimer. The 70kD isoform, 
could not be detected by the N-terminal directed antibody, nor the phospho-ser166 antibody 
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and likely represents a form which is deleted for N-terminal exons. This isoform is consistent 
with the Mdm2A or Mdm2C splice variant products, which lack exons 4 to 9 (amino acids 28 
to 222) or 5 to 9 (amino acids 53 to 222) (respectively) and migrate at approximately this size 
20, 22. The 75kD isoform is phosphorylated on Ser166 and therefore must be encoded by a 
transcript that includes exon 8. Of note, in B-cell lymphomas which arise in Eµc-Myc mice, 
the 70kD form is not expressed, with little or no detection of phospho-50kD, phospho-75kD 
and phospho-FL-Mdm2. Only the ser166-unphosphorylated 75kD isoform was readily 
detected in Eµc-Myc tumours, similar to non-transgenic controls. Bitransgenic tumours, 
expressing both c-Myc and EBNA1 showed a mixed profile (with 50% showing the Mdm2 
induction), which may reflect the degree of functional involvement of EBNA1 in the 
development of each tumour. We have examined over 20 independent tumours from the 
EµEBNA1.26 line and all show this Mdm2 upregulation profile. No Eµc-Myc tumours (over 
10 independent tumours examined) display this Mdm2 activation pattern. Therefore the 
increased phosphorylation of the 50kD, 75kD and FL isoforms and the upregulation of the 
70kD isoform are specific to the EBNA1 driven tumours. It follows that this specific Mdm2 
isoform expression and activation pattern is factorial in EBNA1-driven tumourigenesis. 
 
Inhibition of Mdm2 kills the EBNA1-driven tumour cells and leads to loss of E2F1 
In order to examine the dependency of the transgenic mouse EµEBNA1 tumour cells upon 
Mdm2, we treated cells with Mdm2 inhibitors. Nutlin-3a and SAR405838 bind to Mdm2 
within the p53-binding pockets (thus competing with p53 binding), leading to p53 stability by 
inhibiting its ubiquitin-mediated degradation 23, 24. Nilotinib was developed as an inhibitor of 
c-Abl kinase (for which Mdm2 is a substrate) and this compound causes disruption of the 
Mdm2:Mdmx heterodimer (involving the C-terminal region) and consequent destabilisation 
of Mdm2, and inhibition of the translational promoting activity of Mdm2 upon Xiap mRNA 
25, 26. The small molecule JNJ-26854165 binds to the C-terminal RING domain of Mdm2 and 
inhibits its ubiquitin ligase activity 27. Primary tumour cells isolated from EµEBNA1.26 
transgenic lymphomas were cultured in each drug, with the experiment repeated at least four 
times using different primary tumours (Fig. 8). All four Mdm2 inhibitors led to a significant 
decrease in EµEBNA1 tumour cell viability compared to vehicle-only treated controls, with 
almost complete cell death by 4 days of treatment. In contrast, transgenic Eµc-Myc primary 
lymphoma cells showed no loss of viability with treatment at the same concentration and 
while primary normal leukocytes showed some sensitivity, cultures were still viable after 3 
days of treatment (SI-1 Fig S5 and S6). With the EµEBNA1 tumour cells, all four drugs 
resulted in loss of FL-Mdm2, the 75kD and 50kD ser166 phosphorylated isoforms by day 2, 
and with JNJ, by day 1. Interestingly, the abundant (non-phosphorylated) 70kD isoform was 
more stable. Also, the non-phosphorylated 75kD isoform was lost by day 2 with nutlin-3a and 
SAR treatment, but appeared to be stable with nilotinib and JNJ treatment, thus the drugs 
show differential effect with respect to particular isoforms. While p53 remained stable with 
nutlin-3a treatment, p53 could not be detected after 1 day of treatment with JNJ. Similarly, 
Xiap was undetectable by 1 day of treatment with JNJ, by day 2 with nutlin-3a and SAR 
treatment, but remained detectable over 3 days with nilotinib treatment. EBNA1 levels were 
reduced by day 2 with all 4 drugs. However, the most profound effect of Mdm2 inhibition 
was upon E2F1which was completely lost by day 1 with all 4 drugs. 
To examine the potency of Mdm2 inhibitors upon the EBNA1 tumour cells in 
comparison to other key drug targets, primary tumour cells were treated with inhibitors of c-
Myc, Akt and mTor (10058-F5, Akt-inhbitor II and rapamycin, respectively). At 
recommended doses, the c-Myc inhibitor and nutlin-3a led to rapid death of the cells, while 
rapamycin and the Akt inhbitor had little effect (SI-1 Fig S7). At equimolar doses, the 
increase in rapamycin dose showed effective cell killing (as might be expected of this 
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translational supressor) and the reduced dose of the c-Myc inhibitor showed a reduction in 
killing efficacy while the Akt inhibitor remained ineffectual (Fig 8C).  
Human BL cell lines express several isoforms of the Mdm2 orthologue (Hdm2) and 
little difference was detected between EBV positive and negative or the Mutu cell lines in 
latency I and III (SI Fig S8). However, treatment of these cell lines with the Mdm2 inhibitors 
JNJ and nultiln-3a over 3 days, revealed a difference between EBV in latency I and III, 
consistent with earlier data conducted over 24 hours 28. Raji cells (EBV latency III), 
BL2/B95.8 (transformed with EBV in latency III) and Mutu III (EBV latency III) all showed 
reduced sensitivity to both drugs compared to BL2 (EBV negative) and MutuI (EBV latency 
I) (SI Fig S9). Notably, MutuI cells were largely dead after 3 days culture with both 
inhibitors, while MutuIII showed growth inhibition, but not loss of viability.  
 
 
Discussion 
 
There is a correlation between EBNA1 translation suppression and EBNA1-associated 
tumourigenesis. Mice of the two EBNA1-expressing transgenic lines (EµEBNA1 lines 26 and 
59) develop B-cell lymphoma, but with significantly greater incidence in line 26 6. We 
previously showed that while EBNA1 transcript levels in lymphoid tissues were similar 
between the two lines, EBNA1 protein levels in line 26 before tumour development were far 
lower than line 59, suggesting that the transgene of line 26 is subject to translation 
suppression. We further showed that the transcripts differed between the two lines in the 
utilisation of 5’ start sites, with line 26 showing more initiation upstream of the canonical 
promoter 6. In addition, 3 lines of EBNA1 transgenic mice developed by Kang and 
colleagues, using a different transgene promoter and incorporating a 5’ in-frame FLAG-tag, 
showed high levels of EBNA1 expression and no tumour phenotype 29. Recent studies have 
now provided a solution to the puzzling relationship between EBNA1 translation suppression 
and tumour development. The mechanism of in-cis translation inhibition, mediated by the 
GAr of EBNA1 (and critically dependant upon the configuration of 5’sequences), leads to an 
mRNA translation stress response resulting in an increase in E2F1 synthesis and the 
consequent induction of c-Myc expression, thereby contributing to cell proliferation 5. As 
such, this predicts a direct correlation between EBNA1 translation suppression and 
tumourigenicity by EBNA1, which would be observed as an inverse correlation between 
EBNA1 protein levels (presumably above a basal minimum) and its oncogenic action. This is 
indeed what is observed experimentally, with the line showing highest tumour penetrance 
(line 26) showing low levels of EBNA1 prior to tumour development, and high EBNA1 
expressing mouse lines showing no tumour phenotype 29. 
Prior to the development of tumours, in EµEBNA1.26 B-cells, we observed changes in 
transcript levels of numerous genes, several of which have been previously shown to be 
deregulated by EBNA1 in human cells 9, 10. Amongst these, C-Fos and Stat1 were also shown 
to be upregulated at the protein level in the transgenic mouse tumours and induced in the 
EBV-converted BL2/B95.8 cell line, compared to the parental, EBV negative BL2 cell line, 
which shows no expression. Additionally, parallels could be drawn in a direct comparison of 
gene sets identified with respect to one variable, that of EBNA1 expression, but derived from 
two very different cells systems: the mouse pre-tumour EBNA1 deregulated transcripts, and 
those showing difference after EBNA1-RNAi of an LCL 12. However, while FoxP1 (a tumour 
suppressor), showed lower transcript levels with EBNA1 presence in both systems, this was 
not recapitulated at the protein level, which may reflect a functioning autoregulatory process. 
High-level expression of EBNA1 has been found to inhibit the growth of EBV negative 
BL cell lines 7. However, the higher levels of EBNA1 expression driven from the line 59 
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transgene was not inhibitory to the tumour development observed in line 26 (as observed in 
the 26/59 bitransgenic study). Importantly, investigation of the transgene insertion sites has 
yielded no evidence that cellular genes at these sites contribute to, or inhibit, the tumour 
phenotype, leading to the conclusion that EBNA1 and its pattern of expression in the 
transgenic mouse line 26, is the driving oncogenic force. 
Together these data suggest that EBNA1 is acting as an oncogene through several 
routes in the transgenic mice. Firstly, the mechanism of expression is important, with GAr 
translation suppression being a key contributing factor in the high tumour incidence of line 
26. Secondly, EBNA1 protein-protein interactions are likely to play a role, as Mdm2 (a 
substrate for the EBNA1 binding protein USP7) is critical in the tumourigenic process. 
Thirdly, EBNA1 has an impact upon the expression of cellular genes at the RNA level. This 
may be achieved through the action of EBNA1 as a transcriptional regulator, and/or as a result 
of the first two mechanisms. One consequence of the tumour cell expression profile points to 
T-cell support of the tumours through IL-2, while the induction of PD-L1 suggests that the 
immune response is compromised 30. 
The consistent and dramatic increase in EBNA1 protein levels from pre-tumour tissue 
to tumour, indicates that this is a positive selection force in tumourigenesis. That at least part 
of the oncogenic activity is independent of the translation mechanism and instead is due to 
EBNA1 protein action, is supported by the observation that dominant negative inhibitors of 
EBNA1 (proposed to block EBNA1 function) inhibit the growth of an EµEBNA1 lymphoma 
derived mouse cell line. 
C-Myc upregulation is inextricably associated with the EBNA1 mediated tumourigenic 
process and we previously showed that this is achieved, at least in part, by mutation. The line 
26 tumours commonly harbour trisomy 15 (the location of mouse c-Myc), which was 
completely absent in mice bitransgenic for EµEBNA1 and Eµc-myc as these over-express c-
Myc from the outset. Similarly, the c-myc locus was identified as a common insertion site of 
MoMLV, using the provirus as a mutagenic cooperative gene tag in tumourigenesis in the 
EµEBNA1 mice 13. Accordingly, small molecule inhibition of c-Myc leads to the death of 
these EµEBNA1 tumour cells. This is consistent with BL, in which translocation of the c-Myc 
locus and deregulation of c-Myc expression is a characteristic. 
We now show that deregulation of Mdm2 is a critical event in the process of EBNA1 
mediated tumourigenesis and that specific isoforms are induced and phosphorylated at ser166, 
including full length, 75kD, 50kD and a ser166-non-phosphorylated 70kD C-terminal 
isoform. As Mdm2 is not apparently overexpressed prior to the onset of tumourigenesis, but is 
highly upregulated in every EBNA1 tumour, this is likely to be driven by epigenetic changes 
or mutation and growth advantage selection. Importantly, the levels of expression of Mdm2 
and EBNA1 are linked. Inhibition of Mdm2 leads to loss of Mdm2 and loss of EBNA1 
expression. As well as the complex, mutually regulative functions between Mdm2 and p53, 
Mdm2 facilitates Xiap translation via the C-terminal ring domain 27 and can also act as a 
chaperone, to assist in the protein folding of p53 20, additionally, it plays a role in nucleolar 
stress responses 31. Thus Mdm2 may facilitate EBNA1 translation and/or protein folding. In 
support of this hypothesis, the most highly upregulated isoform of Mdm2 in the EBNA1 
tumours (70kD) lacks part of the N-terminal region, retains the C-terminal region and is 
consistent with the human splice variant Mdm2A which encodes a p53-independant 
oncogenic form of Mdm2 20. Inhibition of Mdm2 in the EBNA1 tumour cells also led to the 
loss of all ser166 phosphorylated species of Mdm2 (FL, 75kD and 50kD and multimers). This 
site is phosphorylated by Akt and enables Mdm2 nuclear localisation and stability. It is not 
known exactly how the inhibitors act, but all four resulted in loss of the ser166-
phosphorylated species, the C-terminal binding compound JNJ-26854165 being the most 
potent.  
	 9	
The cell cycle regulator E2F1 is abundantly overexpressed in all the EBNA1 tumours 
and inhibition of Mdm2 led to rapid loss of E2F1. Mdm2 interacts through both its N-terminal 
region and the RING domain with E2F1 20 and is able to stabilise E2F1 thereby promoting 
cell proliferation 32. However, in p53 wild type cells, E2F1 inhibits Mdm2 expression at the 
promoter, which does not occur in p53 mutant cells 33.  
This leads to our working hypothesis, that in the genesis of these EBNA1 tumours, 
overexpression of Mdm2 enhances both EBNA1 and E2F1 protein expression and stability. 
The E2F1 transactivation function (upon c-Myc and other cell cycle regulators), in 
conjunction with the deregulation of the c-Myc gene by mutation, promotes proliferation. 
Mutation of p53 would facilitate this process by breaking the feedback loop of E2F1 
inhibition upon Mdm2 expression and indeed, C-terminal isoforms of Mdm2 (such as the 
human Mdm2A, B and C isoforms which don’t have the p53 binding domain) have been 
shown to promote expression of mutant p53 and its gain of function action in tumourigeneis 
21, 34. Many other players are clearly involved in the genesis of these EBNA1 driven tumours, 
such as Xiap, which acts to inhibit apoptosis and Mta1, a master co-regulator of gene 
expression and inhibitor of ubiquitination and degradation of p53 18.  
In human BL, all tumours harbour a rearranged c-Myc gene with deregulated 
expression. Similarly most BL tumours have mutant p53 and EBV latency I BL cell lines 
express Mdm2 and are sensitive to Mdm2 inhibition 28. Therefore our transgenic EµEBNA1 
tumour model shares several key features with EBV-positive BL. In culture, EBV positive BL 
cells tend to drift to a latency III state, with the induction of the other viral latent genes. This 
is likely to have a significant impact on the tumorigenic environment, exemplified by the 
action of EBNA2 upon c-Myc 35 and the cells lose sensitivity to Mdm2 inhibition.  
In conclusion, we have shown that EBNA1 is a driving force in the transgenic mouse 
tumours and provides a relevant model for EBV-associated BL, both for investigation and 
testing therapeutic treatment strategies. Deregulation of key cellular genes are required during 
the EBNA1-driven tumourigenic process; as well as c-Myc, Mdm2 induction is pivotal. 
Identification of the latter provides new insight into the role and function of EBNA1 in 
tumourigeneisis and the viral life cycle and opens therapeutic routes for the treatment of EBV 
associated disease. 
 
Materials and Methods 
Mouse microarray data and comparison with human Mutu-LCL RNAseq data.  
RNA was prepared from B-cells, selected from spleens of 2 month old mice (which show no 
pathology), using mouse panB (B220) Dynabeads 15. Five EµEBNA1.26 and 5 negative 
sibling controls (NSC) were used. RNA was polyA selected and cDNA used as a probe on 
Affymetrix arrays (murine genome U74v2:A, B, C ). Genes showing RNA levels with a 
statistically significant difference between transgenic and NSC and with a false error rate 
below 0.05 are listed (SI-2 table S4). 
Information was obtained from the MGI-Mouse vertebrate homology database to 
identify the human homologues of the listed mouse genes. Of these, 114 showed matched 
unique human homologues (74 upregulated in the presence of EBNA1 and 40 
downregulated). Of these, 21 genes showed matched changes in the mouse data set with the 
published Mutu-LCL shRNA data set 12  (13 upregulated in the presence of EBNA1 and 8 
downregulated), with a trend in significance of overlap measured by hypergeometric test 
(p=0.053 and 0.071 respectively). 
 
Transgenic mice and screening. The two transgenic mouse lines, EµEBNA1.26 (line 26) 
and EµEBNA1.59 (line 59), encoding EBNA1 of the B95-8 strain, have been previously 
described 6. Non-transgenic sibling controls (NSC) are used in these studies. Mice were 
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maintained under conventional housing conditions. All procedures have been conducted 
under Home Office licence and the research complied with and was approved by Home 
Office and institutional guidelines, ethical review and policies. Tail genomic DNA was 
prepared 36 and screened by PCR for transgenic status using B and R oligos (SI-1 table 3). 
Samples were also used from mouse lines Eµc-Myc and EµBcl2, described previously 13, 16. 
 
Western blotting. Proteins were extracted in RIPA buffer and separated (10-50µg per track) 
by SDS-PAGE (7.5%, 10% or 4-12% gradient NuPage (Invitrogen)); blotting, blocking, 
washing and detection were performed essentially as previously described 15. Antibodies used 
are listed in SI-1 table S1. At least 3 experimental replicates (tissues from different mice) 
were used to analyse transgenic and NSC samples. 
 
Cell culture and treatments. 
Cells were cultured in RPMI 1640 medium supplemented with 10% FBS, 2mM L-glutamine, 
100 U/ml penicillin, 100µg/ml streptomycin, with 50 µM 2ME for primary cells. Human BL 
cell lines used include: BL2, BL2/B95-8, AK31 (EBV negative derivative of Akata), Raji, 
MutuI and MutuIII. Mouse lymphoma B-cell lines derived from transgenic tumours are: 
39.415 (LMP1 positive) and 3959.48 (LMP1 and EBNA1 positive) 37. Cells were transfected 
by electroporation, and selected by G418 supplement, as detailed 37. Primary lymphoma cells 
explanted from the EµEBNA1.26 line (each tumour from independent mice carry unique I.D. 
numbers), or in vivo passages of these tumours (through C57Bl/6J recipient mice, superscript 
denoting passage number where relevant), or wild type (NSC) splenocytes, were explanted, 
red blood cells lysed (in 0.75%NH4Cl, 0.017M TrispH7.2), and the leukocytes washed 
multiply in PBS and either cultured directly, frozen (90% FBS, 10% DMSO) for subsequent 
culture or analysed by FACS. Cell culture supplements: IL-2 (16ng/ml), IL-6 (1ng/ml), and 
IL-7 (16ng/ml). Drug treatment of cells was by daily addition of Nutlain3a, SAR-405838, 
JNJ-26854165, Nilotinib, C-Myc inhibitor  10058-F4, Akt inhibitor and Rapamycin (SI-1, 
table S2), dissolved at 100x or 1000x in DMSO), for up to 4 days. Live cell counts and 
viability were determined by trypan blue exclusion using the Countess Automated Cell 
Counter (Thermo Fisher Scientific).  
 
Flow cytometry 
Isolated leukocytes (from tumour bearing spleens or controls) were washed in PBS, 1% FBS 
and strained (30µM filter). Cells were preincubated with Trustain (10 mins, ice) and 106 
aliquots used for FACS, staining with conjugated antibodies against surface markers: CD3-
APC, CD4-FITC, CD8-PE, CD19-PE (Ebiosciences). Cells were analysed using a CyAn ADP 
Analyser (Beckman Coulter) and Kaluza software. 
 
FISH 
Explanted splenocytes were washed, and incubated in medium with lipopolysaccharide 
(50µg/ml) for 45hrs, 37oC. Cells were then treated with colcemid (10µg/ml) for 1 hr, 
hypotonically shocked by resuspension in 75mM KCl, collected and fixed in methanol:acetic 
acid (3:1), applied to slides and air dried. A SpectrumGreen or SpectrumRed (Vysis) labelled 
EBNA1 3’ sequence probe (BstXI-EcoRI 1kb transgene fragment) was hybridised, with or 
without chromosome 4 and 5  paint probes (Cambio), to denatured chromosomes, essentially 
as described 38, 39. Samples were counterstained with 0.5µg/ml DAPI in Vectashiled (Vector) 
and examined using a Zeiss Axioplan fluorescent microscope. 
 
Cloning, sequences and plasmids 
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Transgene integration sites were cloned by inverse PCR and phage λ library screening 
(detailed in SI-1). The dominant-negative EBNA1 encoding constructs (generated in 
pcDNA3.1myc-His at BamHI and XbaI sites incorporating in-frame C-terminal myc and His 
tags) are deleted between the natural EBNA1 NcoI and ApaI sites (aa 41 to 435 of EBNA1) 
with the EBNA1 nuclear localisation signal re-inserted at this site (SI-1 table S3). 
GFPdnEBNA1 has inframe fused GFP replacing the N-terminus of EBNA1. 
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Figure legends 
 
Figure 1 
 
The EµEBNA1.26 lymphoma phenotype persists in different strain backgrounds. [A] The 
lymphoma incidence in EµEBNA1.26 mice in the strain background of C57Bl/6 (n=75) was 
compared after crossing the transgene for at least 5 generations (>96.875% backcross strain) 
to mouse strain BalbC (n=47) and FVB (n=39). EµEBNA1.26 mice of strain BalbC started to 
develop B-cell lymphoma at a slightly earlier age (median 192 days) compared to the 
C57Bl/6 strain (median 223 days) and displayed greater lymph node involvement, while mice 
of strain FVB showed a longer latency to B-cell lymphoma development (median 339 days). 
[B] Mice of lines EµEBNA1.26 and EµEBNA1.59 (both in C57Bl/6 strain) were crossbred 
and the lymphoma incidence compared between bi-transgenic (26+59+, n=39) and single 
EµEBNA1.26 positives (26+, n=29) revealing no difference. 
 
Figure 2 
The transgene integration sites. [A] The configuration of the interrupted dimeric transgene in 
line EµEBNA1.59 and the direct dimer in line EµEBNA1.26 are depicted. [B] FISH analysis 
of metaphase chromosomes from hemizygous mice of line EµEBNA1.59 (above) and line 
EµEBNA1.26 (below) are shown, hybridised with an EBNA1 sequence probe (arrows) and 
DAPI counterstained. Middle panels: whole chromosome 4 paint with line 59 samples and 
whole chromosome 5 paint with line 26 samples. Right panels: the transgene containing, 
painted chromosomes magnified. [C] Mapped location of transgene insertion sites in the two 
lines with respect to proximal genes (to scale as indicated).  
 
Figure 3 
T-cells in the tumour environment. [A] Explanted line 26 tumour cells were cultured in 
triplicate, supplemented with combinations of IL-2, IL-6 and IL-7 (as indicated) or no 
supplement (control) and live cell numbers plotted over 20 days.  [B,C,D] Explanted  
leukocytes from spleen tumours (n=12) and aged match non-transgenic, non-tumour controls 
(n=12) were analysed by FACS, with tumour resident T-cells co-stained for CD8, CD4 and 
CD3, flow histogram exemplified in [B]. The ratio of CD8:CD4 is shown by box plot [C] 
comparing the transgenic tumour samples (tg) (mean=6.06) and non-transgenic, non-tumour 
controls (C), mean=0.64 (p=0.0087) and plotted against spleen weight [D] which is indicative 
of tumour burden. [E] Expression (by western) of PD-L1 (with actin loading control below) in 
spleen or lymph node (LN) tumour tissues (T) from transgenic (tg) EµEBNA1.26 (26), or 
Eµc-Myc (c-Myc) mice, alongside non-transgenic, non-tumour control samples (-). 
                                                         
Figure 4 
Dominant negative inhibition of EBNA1. [A] The structure of 3 dominant-negative EBNA1 
encoding constructs is depicted, dn1, dn2 and GFPdn-EBNA1. [B] Transfection of AK31 
cells with GFPdnEBNA1 shows clear nuclear localisation (coincident with DAPI) of the dn 
protein, with strong nucleolar localisation. [C] Flow cytomery shows between 7 and 9% of 
3959.48 cells express control GFP or GFPdnEBNA1 2 days after transfection. [D] 39.415 
(LMP1) and 3959.48 cells (LMP1 and EBNA1) were transfected with empty vector or 
dn1EBNA1 or dn2EBNA1 constructs (as indicated). Aliquots of cells were taken for western 
blotting and EBNA1 detection, 2, 5 and 15 days after transfection and when stable drug-
resistant cultures (S) were established (representative of 3 repeats shown).	 Protein	 size	markers	in	kD	are	indicated	to	the	left	of	each	panel. 
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 Figure	5	
Genes deregulated by EBNA1 in common to mouse and human samples. Genes showing the 
same direction of deregulation in the presence (red in heat map) or absence (blue in heat map) 
of EBNA1 are listed, giving the fold change, mouse and human gene symbols and Entrez ID. 
 
Figure 6 
A selected comparison between mouse and human samples. Protein extracts were examined 
in human and mouse cell lines (A) and from mouse lymph node tissue (B), by western 
blotting for the expression of c-Fos, FoxP1, PCNA, Stat1 and phosphor-tyr-701 Stat1, using 
actin as a loading control (as indicated).	 In	 (A)	 tgT	 is	an	EBNA1	 transgenic	 	 lymph	node	tumour	sample.	 In	(B)	EBNA1	transgenic	status	 is	 indicated	(-/+)	and	no-pathology	or	tumour	 (-,	 T	 respectively)	 above	 each	 track.	 Notes:	 the	 FoxP1	 antibody	 recognizes	 a	doublet	in	human	samples,	with	a	single	band	in	mouse	samples;	the	PCNA	antibody	also	recognizes	 a	 larger	 band	 (~35kD)	 in	 human	 samples;	 the	 p.tyr701-Stat1	 antibody	recognizes	a	doublet	in	both	species,	the	upper	band	of	which	(~90kD)	is	recognized	by	the	antibody	to	total	Stat1.	Protein	size	markers	in	kD	are	indicated	to	the	side	of	each	panel. 
 
Figure 7 
Proteins deregulated in EBNA1 transgenic tumours. Heavily tumour invaded lymph node 
samples (T), or non-tumour controls (tumour -) were analysed by western blotting for the 
expression of EBNA1, c-Myc, E2F1, p53, Xiap, MTA1 and Mdm2, using actin as a loading 
control, or non-specific binding (ns) as loading indicator. For Mdm2, antibodies recognising 
either phosph-ser166 or a C-terminal region were used (p.ser166Mdm2 and C-term-Mdm2 
respectively). Mdm2 isoforms are indicated by size, or full length (FL, migrating at 
approximately 90kD). Each sample represents a distinct primary tumour (tissue taken from 
different mice). Samples were from mice transgenic for EµEBNA1 (line 26), Eµc-Myc, 
bitransgenic for both, or NSC (-), as indicated. Samples were also taken from EµEBNA1.26 
at 2 months old, from normal phenotype lymph nodes prior to development of tumour 
(indicated as EµEBNA1+, tumour -). Note, in these pre-tumour transgenic samples, EBNA1 
expression is below detection at these blot exposures. Protein	 size	 markers	 in	 kD	 are	indicated	to	the	left	of	each	panel. 
 
Figure 8 
Mdm2 inhibitors kill the EBNA1 tumour cells. [A] Diagramatic representation of the domains 
of Mdm2 in linear form, showing the p53 binding region, acidic domain, Zn-finger motif and 
ring domain. Approximate action sites for the inhibitors are shown, with nutlin-3A and 
SAR405838 (SAR) competing with p53 binding, and JNJ26854165 (JNJ) and nilotinib acting 
at the C-terminal region. Epitopes for the antibodies used in these studies are depicted with 
dashed lines: abN: N-terminal epitope, abC: C-terminal epitope and to phosphor-serine166 
(S166). The nuclear localisation signals (NLS) and nucleolar localisation signal (NoLS) are 
shown (arrows). [B] Primary EµEBNA1.26 tumour cells were treated with each Mdm2 
inhibitor (as indicated) at 5µM (2µM for nilotinib), compared to untreated or vehicle only 
(DMSO) and live cell numbers measured for 3 days (triplicate experimental replicates). Error 
bars = SD. [C] Primary EµEBNA1.26 tumour cells were treated with Nutlin-3a, rapamycin 
and inhibitors of c-Myc and Akt (I-c-Myc and I-Akt respectively), all at 5µM, compared to 
untreated or vehicle only (DMSO) and live cell numbers measured for 3 days (in triplicate) 
Error bars = SD. [D] Protein extracts from Mdm2 inhibitor treated tumour cells collected after 
up to 4 days of treatment, compared to untreated cells and non-transgenic leukocytes (WT), 
	 17	
were western blotted, using antibodies as indicated. Representative samples from cells from 
four different tumours are shown (ID: 26.3479, 26.3389, 26.3388, 26.3391 where superscript 
indicates in vivo passage number of the tumour). Protein	size	markers	in	kD	are	indicated	to	the	left	of	each	panel.		
 
 
 
 




E1/no
fold Entrez symbol fold pv 1 2 1 2 Entrez Symbol Description
2.5 11303 Abca1 2.5 0.0001 19 ABCA1 ATP-binding cassette, sub-family A, member 1
1.9 17345 Mki67 2.1 1E-11 4288 MKI67 antigen identified by monoclonal antibody Ki-67
2.3 233016 Blvrb 1.7 0.0172 645 BLVRB biliverdin reductase B (flavin reductase)
2.4 12193 Zfp36l2 1.6 0.0187 678 ZFP36L2 ZFP36 ring finger protein-like 2
2.3 58185 Rsad2 1.6 0.007 91543 RSAD2 radical S-adenosyl methionine domain containing 2
2.5 67712 Slc25a37 1.46 0.0011 51312 SLC25A37 solute carrier family 25 (mitochondrial iron transporter), member 37
2.4 12349 Car2 17 0.0005 760 CA2 carbonic anhydrase II
2.3 78369 Icam4 2.1 0.0216 3386 ICAM4 intercellular adhesion molecule 4 (Landsteiner-Wiener blood group)
1.8 16905 Lmna 1.9 0.0415 4000 LMNA lamin A/C
2.6 209737 Kif15 1.6 0.0024 56992 KIF15 kinesin family member 15
1.9 66447 Mgst3 1.5 0.0288 4259 MGST3 microsomal glutathione S-transferase 3
2.0 65246 Xpo7 1.39 0.0142 23039 XPO7 exportin 7
2.0 114601 Ehbp1l1 1.37 0.0248 254102 EHBP1L1 EH domain binding protein 1-like 1
-2.6 192196 Luc7l2 -1.4 0.0113 51631 LUC7L2 LUC7-like 2
-2.3 108155 Ogt -1.42 0.0067 8473 OGT O-linked N-acetylglucosamine (GlcNAc) transferase
-3.2 170791 Rbm39 -1.43 0.0034 9584 RBM39 RNA binding motif protein 39
-2.5 67120 Ttc14 -1.7 0.0001 151613 TTC14 tetratricopeptide repeat domain 14
-2.7 71175 Nipbl -2.5 0.005 25836 NIPBL Nipped-B homolog
-2.4 76499 Clasp2 -3.7 0.0397 23122 CLASP2 cytoplasmic linker associated protein 2
-1.9 241915 Phc3 -1.32 0.0386 80012 PHC3 polyhomeotic homolog 3
-2.2 108655 Foxp1 -2.3 0.0059 27086 FOXP1 forkhead box P1ge
ne
ex
on
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